Geographic Atrophy in Dry AMD

Andre Witkin, MD

Title: A Randomized, Double Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration

Brief Summary
To assess the safety and effectiveness of the investigational drug ORACEA┬«, to determine if it can slow the progression of geographic atrophy in your study eye in participants who have geographic atrophy secondary to non-exudative age-related macular degeneration (dry AMD). 

Inclusion Criteria

Study Requirements
6 study visits over a 25-month period with additional testing
Age Range

55-85

Gender
Both

Payment
None

Contact: Carly Satsuma, 617-636-5489